BR112019005732A2 - proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose - Google Patents

proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose

Info

Publication number
BR112019005732A2
BR112019005732A2 BR112019005732A BR112019005732A BR112019005732A2 BR 112019005732 A2 BR112019005732 A2 BR 112019005732A2 BR 112019005732 A BR112019005732 A BR 112019005732A BR 112019005732 A BR112019005732 A BR 112019005732A BR 112019005732 A2 BR112019005732 A2 BR 112019005732A2
Authority
BR
Brazil
Prior art keywords
tuberculosis
assays
diagnosis
mycobacterium tuberculosis
diagnostic devices
Prior art date
Application number
BR112019005732A
Other languages
English (en)
Inventor
T Nguyen Hiep-Hoa
Original Assignee
Pace Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pace Diagnostics Inc filed Critical Pace Diagnostics Inc
Publication of BR112019005732A2 publication Critical patent/BR112019005732A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção fornece um método para detectar anticorpos em uma amostra a partir de um sujeito, em que os anticorpos se ligam aos epítopos de antígenos de mycobacterium tuberculosis, que compreende contatar a amostra com dois ou mais polipeptídeos isolados ou fragmentos antigênicos ou as variantes dos mesmos, em que os polipeptídeos compreendem polipeptídeos selecionados a partir do grupo que consiste em seq id nos: 1, 3, 5, 7, 9, 11, 13, e 15; e detectar a formação de complexos anticorpo-peptídeo isolados compreendendo os referidos polipeptídeos ou fragmentos antigênicos ou as variantes dos mesmos, em que a formação dos referidos complexos é indicativa da presença de anticorpos para epítopos de antígenos de mycobacterium tuberculosis na referida amostra.
BR112019005732A 2016-09-22 2017-11-22 proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose BR112019005732A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398213P 2016-09-22 2016-09-22
PCT/US2017/063154 WO2018068064A2 (en) 2016-09-22 2017-11-22 Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis

Publications (1)

Publication Number Publication Date
BR112019005732A2 true BR112019005732A2 (pt) 2019-08-06

Family

ID=61831255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005732A BR112019005732A2 (pt) 2016-09-22 2017-11-22 proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose

Country Status (7)

Country Link
US (1) US20190293645A1 (pt)
EP (2) EP4257976A3 (pt)
CN (1) CN110073215B (pt)
BR (1) BR112019005732A2 (pt)
CA (1) CA3059408A1 (pt)
MX (1) MX2019003288A (pt)
WO (1) WO2018068064A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113740529B (zh) * 2021-08-25 2023-05-26 华中农业大学 一种犬吉氏巴贝斯虫抗体乳胶凝集检测试剂盒及其制备方法和应用
KR20240048548A (ko) * 2021-08-25 2024-04-15 문정주 Covid-19 감염 검출을 위한 카르복실 라텍스 비드와 비오틴-폴리스트렙타비딘을 이용한 측면 유동 분석법 및 측면 유동 분석법을 이용한 진단 키트

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2154248E (pt) * 1995-09-01 2012-01-16 Corixa Corp Compostos e métodos para diagnóstico de tuberculose
US6458366B1 (en) * 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US6291190B1 (en) * 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
US20040018574A1 (en) * 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
ES2364520T3 (es) * 1998-08-25 2011-09-06 The Board Of Trustees Of The Leland Stanford Junior University Marco de lectura abierto rv2660c de m. tuberculosis y su utilización.
AU2002302919A1 (en) * 2001-02-22 2002-10-03 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20060046310A1 (en) 2004-08-25 2006-03-02 Zong-Li Xia Amplification method for solid phase immunoassays
EP2441469A1 (en) * 2006-03-14 2012-04-18 Oregon Health and Science University Methods for producing an immune response to tuberculosis
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
US7776618B2 (en) 2007-03-01 2010-08-17 Church & Dwight Co., Inc. Diagnostic detection device
CN102718848A (zh) * 2012-06-01 2012-10-10 上海交通大学 结核分枝杆菌Rv3120的重组蛋白、其制备方法及其在细胞免疫诊断中的应用

Also Published As

Publication number Publication date
WO2018068064A9 (en) 2018-05-31
EP3516394A4 (en) 2020-09-02
CN110073215A (zh) 2019-07-30
MX2019003288A (es) 2019-11-05
CA3059408A1 (en) 2018-04-12
EP3516394A2 (en) 2019-07-31
EP4257976A3 (en) 2024-01-24
EP3516394C0 (en) 2023-06-21
WO2018068064A2 (en) 2018-04-12
WO2018068064A3 (en) 2018-06-28
EP4257976A2 (en) 2023-10-11
CN110073215B (zh) 2024-04-30
EP3516394B1 (en) 2023-06-21
US20190293645A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
BR112014017645A2 (pt) molécula imunológica; polinucleotídeo; vetor; célula recombinante que compreende o vetor; método para produzir molécula imunológica; anticorpo ou fragmento de ligação de antígeno do mesmo; composição farmacêutica; uso da molécula imunológica, do anticorpo, do fragmento de ligação de anticorpo ou da composição farmacêutica; método diagnóstico para diagnosticar uma doença em um indivíduo, em que a doença é selecionada do grupo que consiste em câncer, uma doença autoimune ou uma doença infecciosa; ensaio para diagnosticar uma doença em uma amostra de tecido tomada de um indivíduo; uso de um anticorpo ou um fragmento que se liga especificamente à seq id no: 10; e método diagnóstico para determinar se realiza o uso ou administra a composição
BR112018016337A2 (pt) anticorpos monoclonais da proteína ns1 de vírus antidengue
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112015022844A2 (pt) métodos para detecção de anticorpos para doadores específicos e sistemas para pratica destes
BR112018014122A2 (pt) imunoensaio para o diagnóstico de infecções virais
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112015023355A8 (pt) antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
BR112018005812A2 (pt) ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico?
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
BR112014020513A2 (pt) Métodos e sistemas para amplificação de sinal de bioensaios
BR112019005732A2 (pt) proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
BR112015022548A2 (pt) método de separação de células usando immunorosettes e partículas magnéticas
BR112018075414A2 (pt) método para detectar a presença de material micobacteriano em uma amostra com o uso de pelo menos dois antígenos, substrato sólido e biossensor
JP2015529211A5 (pt)
BR112017003778A2 (pt) compostos contra ralstonia pickettii para o uso no tratamento de resistência à insulina e método de diagnóstico de resistência à insulina
BR112017019236A2 (pt) kit, e, método para detectar a presença de anticorpos de sífilis em uma amostra
JP2017524689A5 (pt)
BR112017006215A2 (pt) método para detectar uma proximidade espacial de um primeiro e um segundo epítopos, método para estratificação de um indivíduo, kit para realizar o método, e, uso do kit
BR112016021714A2 (pt) imunoensaio e anticorpos para a detecção de cromogranina a

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: VIDE PARECER

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 15.9 NA RPI NO 2551 DE 26/11/2019 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023007224-3 PROTOCOLO 870230032291 EM 18/04/2023 14:02.